FDA Confirms B. Magi Weight-Loss Supplement Contains Undeclared Toxic Yellow Oleander Derivatives

Undeclared cardiac glycosides and a probable carcinogen found in a commercially available weight-loss product signal a raw material adulteration risk that QA directors cannot address through label review alone. FDA laboratory analysis of B. Magi, a supplement sold on multiple websites including www.lamilagrosalab.com and potentially in retail stores, confirmed the presence of three substances absent from the product label: phenolphthalein, neriifolin, and thevetin B.

Phenolphthalein, once used as a laxative active ingredient, carries no approved drug status in the U.S. and is associated in studies with increased cancer risk. Neriifolin and thevetin B are cardiac glycosides derived from the yellow oleander plant (Thevetia peruviana) and carry documented potential for neurologic, gastrointestinal, and cardiovascular adverse effects, including fatalities. Neither compound would appear on a standard dietary supplement panel without targeted analytical testing.

For QA leads overseeing incoming raw material controls, the case reinforces a persistent gap: supplier-provided certificates of analysis and label declarations are insufficient to detect deliberate or incidental adulteration of this type. Products in the weight-loss, sexual enhancement, pain relief, and bodybuilding categories have historically represented the highest concentration of tainted supplement notifications from FDA, and this notification follows that pattern. Orthogonal testing methods, including LC-MS/MS screening for undeclared pharmacologically active compounds, are increasingly necessary at the raw material intake stage rather than solely at finished-product release.

FDA acknowledged directly that it cannot test and identify all potentially adulterated products marketed as dietary supplements, placing the burden of supply chain vigilance on manufacturers and distributors operating under 21 CFR Part 111 dietary supplement GMP requirements. Healthcare professionals and consumers are directed to report adverse events through FDA's MedWatch program, either via the online voluntary reporting form or by fax at 1-800-FDA-0178.

The agency's tainted supplements database and its dedicated Medication Health Fraud resources remain the primary reference points for tracking active notifications, and QA teams sourcing from third-party suppliers in the weight-management category should cross-reference those listings as part of approved supplier qualification reviews.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications, via FDA.gov, August 12, 2026.